Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

IVF hormone showdown: does adding LH boost egg quality?

NCT ID NCT07348757

Knowledge-focused Sponsor: Centrum Clinic IVF Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at two common hormone treatments for women undergoing IVF: one using only FSH and another using both FSH and LH. All 202 participants also received dydrogesterone to control hormone surges. Researchers measured how many mature eggs were collected and how embryos developed. The goal was to see if adding LH makes a difference in these outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
recombinant FSH and recombinant LH (hormones used in IVF)
What this could lead to
If it works, this could help doctors choose the best hormone combination for IVF, potentially improving egg and embryo quality.
What could go wrong
This is a small, completed study with 202 participants, so results may not apply to all women. Adding LH may not provide any benefit over FSH alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

202 people

The number who actually took part.

Started

Feb 2026

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants will be selected from women seeking infertility treatment at a fertility clinic and undergoing in-vitro fertilization (IVF) with controlled ovarian stimulation. This population typically consists of reproductive-age women who have difficulty achieving pregnancy and require assisted reproductive technologies. Eligible patients are generally healthy enough to undergo ovarian stimulation, have adequate ovarian reserve (AMH \> 1 ng/mL), and meet age and BMI criteria for standard IVF care. Women in this group routinely receive dydrogesterone-based PPOS protocols as part of their clinical treatment, and the choice of gonadotropin regimen (rFSH alone or rFSH+rLH) follows routine medical practice. This population reflects real-world patients commonly treated in IVF programs

Ages

18 to 43 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women aged 20 to 43 years. * BMI \< 30 kg/m². * AMH \> 1 ng/mL. * Undergoing IVF/ICSI treatment with a dydrogesterone-based PPOS protocol. * Women with regular menstrual cycles or clinically acceptable cycle pattern for stimulation. * Ability to provide informed consent and comply with study procedures. * Presence of at least one ovary and eligibility for controlled ovarian stimulation Exclusion Criteria: * Cycle cancellation due to lack of viable embryos. * Prior or planned PGT-A in the same cycle. * Adenomyosis diagnosed by ultrasound or MRI. * Uncorrected uterine anomalies (e.g., bicornuate, unicornuate, didelphys uterus). * Presence of hydrosalpinx. * Use of oral contraceptives or luteal-phase estradiol within 3 months before stimulation. * Refusal or inability to provide informed consent. * Severe systemic disease or contraindication to ovarian stimulation. * Prior bilateral oophorectomy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gonadotropins are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gonadotropins Invitro fertilization

Contacts and locations

Locations

  • Bahçeci IVF Center

    Ankara, Turkey (Türkiye)

  • Centrum Clinic IVF Center

    Ankara, Ankara, 06800, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.